Cognition Therapeutics (CGTX) Price & Analysis

Compare

517 Followers

CGTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.22 - $3.83

Previous CloseN/A

Volume950.02K

Average Volume (3M)9.46M

Market Cap

$214.38M

Enterprise Value$8.64M

Total Cash (Recent Filing)$10.74M

Total Debt (Recent Filing)$427.00K

Price to Earnings (P/E)―

Beta2.16

Next Earnings

Nov 12, 2025

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding88,223,885

10 Day Avg. Volume11,277,343

30 Day Avg. Volume9,457,508

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.04

Enterprise Value/Revenue34.57

Enterprise Value/Gross Profit-34.99

Enterprise Value/Ebitda-0.19

Forecast

1Y Price Target

$3.00

Price Target Upside23.46% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe Phase 3 program for zervimesine will use an enrichment methodology involving a biomarker (p-tau217) linked to enhanced responsiveness, which is highly encouraging.

Regulatory ProgressFavorable FDA feedback on zervimesine's clinical pathway in Alzheimer's disease is a significant step forward for Cognition Therapeutics.

Bears Say

Regulatory UncertaintyCognition Therapeutics is awaiting formal regulatory feedback on multiple fronts to inform clinical development of its lead candidate zervimesine in both Alzheimer's disease and dementia with Lewy bodies.

Trial ComplexityThe FDA feedback would constitute meaningful clarity and a clear value inflection point for Cognition, particularly if it mandated a 12-month evaluation period and stipulated a single functional outcome measure as a primary endpoint.

Cognition Therapeutics News

Cognition Therapeutics announces $30M registered direct offering of common stock

Titan Partners Group, a division of American Capital Partners, is acting as the sole placement agent for the...

6d ago

CGTX

Cognition Therapeutics regains compliance with Nasdaq

Cognition Therapeutics (CGTX) was notified by Nasdaq that the company has regained compliance with the exchange’s continued listing...

7d ago

CGTX

Cognition Therapeutics confirms aligment with FDA on path for zervimesine

Cognition Therapeutics (CGTX) received final minutes from the FDA pertaining to the end-of-Phase 2 meeting that was conducted...

21d ago

CGTX

Cognition Therapeutics reports Q2 EPS (11c), consensus (10c)

“The second quarter of 2025 has been very productive, with milestones from each of our clinical programs,” stated...

26d ago

CGTX

Cognition Therapeutics Announces $30.1M Direct Offering

Cognition Therapeutics ( ($CGTX) ) has issued an update. On August 27, 2025, Cognition Therapeutics, Inc. announced it...

5d ago

CGTX

Cognition Therapeutics Regains Nasdaq Compliance

Cognition Therapeutics ( ($CGTX) ) has issued an update. Cognition Therapeutics, Inc. received a deficiency letter from Nasdaq...

7d ago

CGTX

Cognition Therapeutics Reports Q2 2025 Financial Results

Cognition Therapeutics, Inc. ( ($CGTX) ) has released its Q2 earnings. Here is a breakdown of the information...

19d ago

CGTX

Promising Developments and Regulatory Milestones Drive Buy Rating for Cognition Therapeutics

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cognition Therapeutics and keeping the price target...

23d ago

CGTX

Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors

Cognition Therapeutics, Inc. (($CGTX)) announced an update on their ongoing clinical study. The recent clinical study update from...

1M ago

CGTX

Cognition Therapeutics presents data at AAIC on CT1812 in dementia

Cognition Therapeutics (CGTX) presented results from the Phase 2 COG1201 SHIMMER study of zervimesine, CT1812, in dementia with...

1M ago

CGTX

Cognition Therapeutics publishes results of analysis from Phase 2 SEQUEL study

Cognition Therapeutics (CGTX) published results of a proteomics analysis from the Phase 2 ‘SEQUEL’ COG0202 Study of zervimesine...

1M ago

CGTX

Cognition Therapeutics ot present data from zervimesine Phase 2 study

Cognition Therapeutics (CGTX) announced that James Galvin, MD, MPH will present results from the Phase 2 ‘SHIMMER’ study...

2M ago

CGTX

Cognition Therapeutics Receives Buy Rating Amid Promising Developments and Regulatory Advancements for Zervimesine

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Cognition Therapeutics. The associated price target...

2M ago

CGTX

Cognition completes End-of-Phase 2 meeting with FDA for zervimesine

Cognition Therapeutics (CGTX) conducted an end-of-Phase 2 meeting with the U.S. Food and Drug Administration on July 9,...

2M ago

CGTX

CGTX FAQ

What was Cognition Therapeutics’s price range in the past 12 months?

Cognition Therapeutics lowest stock price was $0.22 and its highest was $3.83 in the past 12 months.

What is Cognition Therapeutics’s market cap?

Cognition Therapeutics’s market cap is $214.38M.

When is Cognition Therapeutics’s upcoming earnings report date?

Cognition Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 70 days.

How were Cognition Therapeutics’s earnings last quarter?

Cognition Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.105 by -$0.005.

Is Cognition Therapeutics overvalued?

According to Wall Street analysts Cognition Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cognition Therapeutics pay dividends?

Cognition Therapeutics does not currently pay dividends.

What is Cognition Therapeutics’s EPS estimate?

Cognition Therapeutics’s EPS estimate is -0.1.

How many shares outstanding does Cognition Therapeutics have?

Cognition Therapeutics has 88,223,885 shares outstanding.

What happened to Cognition Therapeutics’s price movement after its last earnings report?

Cognition Therapeutics reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.105. Following the earnings report the stock price went up 10.294%.

Which hedge fund is a major shareholder of Cognition Therapeutics?

Among the largest hedge funds holding Cognition Therapeutics’s share is Carlson Capital LP. It holds Cognition Therapeutics’s shares valued at 0.

Cognition Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-219.68%

Trailing 12-Months

Asset Growth

-42.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cognition Therapeutics

Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of neurodegenerative diseases, such as Alzheimer's disease and other central nervous system disorders. The company's core product candidates are small molecule therapeutics designed to target synaptic dysfunction by modulating key protein interactions involved in the pathology of these diseases.

Cognition Therapeutics (CGTX) Earnings & Revenues

Historic Earnings Reports

CGTX Stock 12 Month Forecast

Average Price Target

$3.00

▲(23.46% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.8492307692307692,1.0284615384615385,1.2076923076923078,1.3869230769230771,1.5661538461538465,1.7453846153846153,1.9246153846153846,2.103846153846154,2.2830769230769232,2.4623076923076925,2.641538461538462,2.8207692307692307,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.8492307692307692,1.0284615384615385,1.2076923076923078,1.3869230769230771,1.5661538461538465,1.7453846153846153,1.9246153846153846,2.103846153846154,2.2830769230769232,2.4623076923076925,2.641538461538462,2.8207692307692307,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.67,0.8492307692307692,1.0284615384615385,1.2076923076923078,1.3869230769230771,1.5661538461538465,1.7453846153846153,1.9246153846153846,2.103846153846154,2.2830769230769232,2.4623076923076925,2.641538461538462,2.8207692307692307,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.67,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >